Press release
Vitiligo Pipeline Advancements Report 2025: DelveInsight Highlights Emerging Therapeutics Reshaping the Treatment Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Vitiligo Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Vitiligo Pipeline Report
* On 20 November 2025, Incyte Corporation announced a Phase 3 study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
* On 17 November 2025, National Institute of Allergy and Infectious Diseases (NIAID) conducted a study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.
* On 10 November 2025, AbbVie conducted a study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in disease activity will be assessed.
* On 10 November 2025, Takeda initiated a study is to learn how safe dacomitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months.
* DelveInsight's Vitiligo pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Vitiligo treatment.
* The leading Vitiligo Companies such as Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc . and others.
* Promising Vitiligo Pipeline Therapies such as Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others.
Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight's in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Vitiligo Emerging Drugs Profile
* Povorcitinib: Incyte Corporation
Povorcitinib (INCB54707) is an oral, selective JAK1 inhibitor developed by Incyte as a potential treatment for vitiligo. It works by targeting the JAK-STAT signaling pathway, which is involved in the immune system's attack on melanocytes, the pigment-producing cells in the skin. By inhibiting JAK1, Povorcitinib aims to reduce inflammation and halt the immune-mediated destruction of melanocytes, thereby promoting repigmentation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Vitiligo.
* VYN201: Vyne Therapeutics Inc.
VYN201 (Repibresib) is a locally administered pan-BET inhibitor designed to target multiple inflammatory signaling pathways with minimal systemic exposure. It binds to both BD1 and BD2 bromodomains, offering broad anti-inflammatory activity. Its soft drug design allows for targeted treatment of conditions like vitiligo while minimizing systemic side effects. Repibresib shows potential for other inflammatory skin disorders benefiting from localized therapy. Currently, the drug is being evaluated in Phase II stage of its clinical trial for the treatment of Vitiligo.
* MK-6194: Merck Sharp & Dohme LLC
MK-6194 is an investigational IL-2 mutein, a modified form of interleukin-2 designed to selectively activate regulatory T cells (Tregs). It is being studied as a potential treatment for non-segmental vitiligo, a condition where patches of skin lose their pigment. By boosting Treg activity, MK-6194 aims to help control the autoimmune response that contributes to pigment loss. This targeted approach may support repigmentation and reduce the extent of vitiligo patches. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Vitiligo.
The Vitiligo Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
* Vitiligo Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market.
Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight's expert-driven report today! @ Vitiligo Unmet Needs [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Vitiligo Companies
Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc . and others.
Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Vitiligo Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Vitiligo Pipeline Report
* Coverage- Global
* Vitiligo Companies- Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc . and others.
* Vitiligo Pipeline Therapies- Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others.
* Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight's exclusive Vitiligo Pipeline Report-access it now! @ Vitiligo Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Vitiligo: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Vitiligo- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Afamelanotide: Clinuvel, Inc.
* Mid Stage Products (Phase II)
* VYN201: Vyne Therapeutics Inc.
* Early Stage Products (Phase I)
* FB102: Forte Biosciences, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Vitiligo Key Companies
* Vitiligo Key Products
* Vitiligo- Unmet Needs
* Vitiligo- Market Drivers and Barriers
* Vitiligo- Future Perspectives and Conclusion
* Vitiligo Analyst Views
* Vitiligo Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vitiligo-pipeline-advancements-report-2025-delveinsight-highlights-emerging-therapeutics-reshaping-the-treatment-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vitiligo-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vitiligo Pipeline Advancements Report 2025: DelveInsight Highlights Emerging Therapeutics Reshaping the Treatment Landscape here
News-ID: 4288309 • Views: …
More Releases from ABNewswire
Augure Enters the AI Race Against OpenAI and Anthropic - Staking Its Claim on Ca …
Canadian startup Augure launches a sovereign AI platform that directly challenges OpenAI and Anthropic for regulated professionals. By hosting all data on Montreal servers, Augure eliminates US CLOUD Act exposure for defense contractors, lawyers, and therapists. The platform arrives as CPCSC deadlines, Law 25, and PIPEDA compliance pressures make US-hosted AI tools untenable for Canadian organizations.
TORONTO, ON - In an AI market dominated by American hyperscalers, a Canadian company is…
Chicago Divorce Attorney Russell D. Knight Guides Clients Through QDRO Requireme …
CHICAGO, IL - Dividing tax-deferred retirement accounts in Illinois divorce requires a Qualified Domestic Relations Order to preserve the accounts' tax-deferred status and avoid early withdrawal penalties. Chicago divorce attorney Russell D. Knight of the Law Office of Russell D. Knight (https://rdklegal.com/what-is-a-qdro-in-an-illinois-divorce) explains the QDRO process and how couples can divide retirement funds without incurring tax consequences.
According to Chicago divorce attorney Russell D. Knight, a Qualified Domestic Relations Order is…
Manhattan Real Estate Attorney Peter Zinkovetsky Explains What Makes a Real Esta …
MANHATTAN, NY - Real estate contracts in New York require specific elements to be legally enforceable, and understanding what makes a contract executed is essential for buyers and sellers navigating property transactions. Manhattan real estate attorney Peter Zinkovetsky of Avenue Law Firm (https://www.avenuelawfirm.com/what-is-an-executed-real-estate-contract/) is providing guidance on executed contracts and the critical stages between signing and closing.
According to Manhattan real estate attorney Peter Zinkovetsky, the term "executed" carries two distinct…
Independent Analysis of 100 UAE Real Estate Developers in Comprehensive 2026 Res …
The UAE real estate market produced record transaction volumes in 2025. But transaction volume and informed decision-making are not the same thing. Buyers, investors, and developers operating in this market deserve access to independent, data-driven analysis that is not shaped by commercial relationships with the developers being evaluated. UAE Developers Decoded is written with that standard as its only objective. It is available free because access to accurate market intelligence…
More Releases for Vitiligo
Organic Care Australia Introduces 'Vitiligo Organics' - A Revolutionary Herbal T …
Image: https://www.getnews.info/uploads/39ec7fd227c4937add1acccc27f32c1b.jpg
Organic Care Australia proudly announced the launch of 'Vitiligo Organics' in 2009, a revolutionary herbal treatment that promises new hope for individuals living with vitiligo, a condition characterized by the loss of skin pigmentation resulting in white patches. This innovative product represents a significant breakthrough in the management of vitiligo, offering a natural, effective solution for those who have long sought an alternative to conventional treatments.
Vitiligo impacts millions worldwide,…
Vitiligo Treatment Market - Unleash Your True Colors: Breakthrough Vitiligo Trea …
Newark, New Castle, USA: The "Vitiligo Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Vitiligo Treatment Market: https://www.growthplusreports.com/report/vitiligo-treatment-market/7780
This latest report researches the industry structure, sales, revenue,…
Vitiligo - Drug Pipeline Landscape, 2022
Vitiligo is a chronic disorder that causes patches of skin to lose pigment or color, when melanocytes are attacked and destroyed, causing the skin to turn a milky-white color. There are two types of vitiligo such as nonsegmental or generalized vitiligo and segmental vitiligo. Nonsegmental or generalized vitiligo happens when the white patches appear symmetrically on both sides of body, such as on both hands or both knees. Segmental vitiligo…
Vitiligo Treatment Market: Rising Impressive Business Opportunities Analysis For …
Vitiligo Treatment Market Report 2022: Industry aims to provide an overview of the industry through detailed market segmentation. The report offers thorough information about the overview and scope of the market along with its drivers, restraints, and trends. This report is designed to include both qualitative and quantitative aspects of the industry in each region and country participating in the study.
Get a Sample PDF of the Report @ https://impeccablemarketresearch.com/enquiry/request-sample-pdf/14636671?utm_source=Openpr&utm_medium=Shubhamko
…
Vitiligo Skin Disorder
Vitiligo Skin Disorder
Vitiligo skin disorder is a skin condition in which white patches on the skin are formed due to malfunctioning of melanocytes, cells that promote pigmentation. http://www.curevitiligooil.com/Vitiligo-Skin-Disorder.htmlThe start of this disease and the grimness of pigment loss vary from person to person. People who have light skin usually witness the loss of pigment in summers because the contrast between depigmented skin and sunburned skin appears distinctive. On the other…
Vitiligo Symptoms
Vitiligo produces macules which are small areas of different skin color. The skin disorder may also produce patches which are flat, pale or white and can't be felt with fingers. (http://www.curevitiligooil.com/Vitiligo-Symptoms.html). These marks frequently expand to form very large, irregularly-shaped areas with no pigmentation. Typically, these are painless and do not itch. The cause of vitiligo symptoms is not known, but autoimmunity may be a factor. Since it is a…
